Comparative Pharmacology
Head-to-head clinical analysis: CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER versus FORTAZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER versus FORTAZ.
CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER vs FORTAZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftriaxone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking. It has bactericidal activity against a broad range of gram-positive and gram-negative bacteria.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, leading to cell lysis.
1-2 g intravenously or intramuscularly every 24 hours. Maximum dose: 4 g daily.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day for serious infections.
None Documented
None Documented
Terminal elimination half-life is approximately 5.8-8.7 hours in adults, prolonged to 12-24 hours in elderly, and up to 30-72 hours in neonates. No dose adjustment in renal impairment alone; adjust in severe hepatic impairment.
2 hours (normal renal function); prolonged to 12-20 hours in ESRD
Renal (33-67% unchanged) and biliary (up to 40% as unchanged drug and microbiologically inactive metabolites); fecal elimination of unabsorbed drug is minimal. Dose adjustment required in combined renal and hepatic impairment.
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; 5-10% biliary/fecal
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic